Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis ; volume:17 ; number:1 ; day:10 ; month:9 ; year:2019 ; pages:1-10 ; date:12.2019
Pediatric rheumatology ; 17, Heft 1 (10.9.2019), 1-10, 12.2019
- Urheber
-
Khraishi, Majed
Millson, Brad
Woolcott, John
Jones, Heather
Marshall, Lisa
Ruperto, Nicolino
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-019-0358-x
- URN
-
urn:nbn:de:101:1-2020012501104741323451
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Khraishi, Majed
- Millson, Brad
- Woolcott, John
- Jones, Heather
- Marshall, Lisa
- Ruperto, Nicolino
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis